Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1 Endocrine 1

Conditions

Neuroendocrine Tumors 14 Carcinoid Tumor 5 Gastro-enteropancreatic neuroendocrine tumor 4 Acromegaly 3 Serotonin Syndrome 2 Pituitary Neoplasms 2 Pheochromocytoma 1 Paraganglioma 1 Neuroendocrine Tumour With Carcinoid Symptoms 1 Neuroendocrine Tumors in Lung 1 Neoplastic Cells, Circulating 1 Neoplasm Metastasis 1 Growth Hormone-Secreting Pituitary Adenoma 1 Gigantism 1 Gastrointestinal Neoplasms 1 Flushing 1 Diarrhea 1 Carcinoma, Hepatocellular 1 Carcinoid Heart Disease 1 Adenoma, Islet Cell 1

Interventions

Doxorubicin 4 Sunitinib 3 Radiosurgery 3 Everolimus 3 pembrolizumab 2 exemestane 2 Tamoxifen 2 Specimen Handling 2 Octreotide 2 Magnetic Resonance Spectroscopy 2 Fulvestrant 2 Filgrastim 2 Biopsy 2 Bevacizumab 2 3-Iodobenzylguanidine 2 tislelizumab 1 surufatinib 1 romidepsin 1 regorafenib 1 penpulimab 1 pasireotide 1 mercaptoundecahydrododecaborate 1 lutetium Lu 177 dotatate 1 lanreotide 1 ganitumab 1 folfirinox 1 fludarabine phosphate 1 epothilone B 1 entrectinib 1 dostarlimab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm Metastasis × lanreotide × Endocrine × Clear all

NCT01731925 2017-01-31

SUNLAND

GERCOR - Multidisciplinary Oncology Cooperative Group

Phase 2 Unknown

Carcinoid Tumor, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡